Earth Science Tech, Inc. (OTC: ETST) received FINRA clearance on December 12 2025 to begin priced quotations on the over‑the‑counter market, a decision announced on December 15 2025. The clearance was granted after the company’s Form 211 filing satisfied FINRA Rule 6432 and the Securities Exchange Act’s Rule 15c2‑11, confirming that the sponsoring broker‑dealer met all regulatory requirements for quotation initiation.
The Form 211 approval is a key regulatory hurdle for any issuer seeking OTC pricing. By meeting FINRA’s information and disclosure standards, ETST now has the framework to offer its shares to a broader investor base, improving liquidity and market visibility. The approval also signals that the company’s financial and operational disclosures meet the transparency thresholds required for priced quotations, a prerequisite for many institutional investors.
ETST is a holding company with interests in pharmaceutical compounding, telemedicine, real estate, and consumer products. In the most recent quarter, the company reported revenue of $7.35 million, up 94% year‑over‑year from $3.79 million in the same period a year earlier, driven by growth in its core segments. Net income, however, fell due to higher operating expenses, reflecting the company’s investment in scaling its businesses. The new OTC pricing capability is expected to enhance ETST’s ability to raise capital and support its expansion plans across these sectors.
CEO and Chairman Giorgio R. Saumat described the clearance as a “critical milestone in our strategic plan.” He added that the ability to trade priced quotations will help build long‑term shareholder value by improving liquidity and enabling the company to execute its growth initiatives more effectively. The statement underscores management’s confidence that the regulatory approval will translate into tangible benefits for investors and the company’s strategic objectives.
While no immediate market reaction data is available, the clearance opens the door for priced quotations, potentially attracting a wider range of investors and increasing the visibility of ETST’s shares. The regulatory approval is a foundational step that could support future capital‑raising efforts and provide a more robust platform for the company’s diversified business portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.